GlobalRPh Renal Dosing Masterv6.6
GlobalRPh source record

Fenofibrate (Tricor)

Local RX List renal extractBase record retrieved 2026-09-05See the evidence for this drug2 sources available - open source summaries, references and comparisons
READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (2)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

2 additional source qualifications - review before use
Fenofibrate renal starting strengths are product-specific

TRICOR uses its own starting strength. ANTARA, LIPOFEN and FENOGLIDE have different strengths; TRIGLIDE has a distinct lower-dose availability restriction.

Before applying: Confirm the dispensed formulation and its own renal instructions. Do not apply a generic milligram-equivalence rule.

Source-identity hold: title strength does not match capsule description

The separate RX fenofibrate-drug page is titled 40/120 mg but describes 50/150 mg capsules. No renal dosing from that mismatched page was imported in v4.1.

Before applying: Use the verified named-product source, not the held generic page. See the F audit entry for its retrieval reference. This is a source-quality problem, not a clinical disagreement.

Also check: Fenofibrate renal starting strengths are product-specific; Source-identity hold: title strength does not match capsule description

Rxlist source

GlobalRPh RX List - TRICOR

Product / population
Fenofibrate TRICOR tablets, 48/145 mg.
Renal measure
eGFR in mL/min/1.73 m2.

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Renal dosing, restrictions and evidence limits

eGFR 30 to <60 mL/min/1.73 m2: start 48 mg orally once daily. Increase only after assessing renal function and triglyceride response. Use is contraindicated at eGFR <30 mL/min/1.73 m2, including ESRD and dialysis. Assess renal function before treatment and periodically during therapy. The starting strength belongs to this named product.

Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-07. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/tricor-drug/

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 2 source difference / applicability notes

Preserved GlobalRPh source

Preserved original GlobalRPh source

Preserved historical content; not revalidated as current prescribing guidance.

Renal method: Read the measure and population stated in the original source sections.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - TRICOR

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Fenofibrate TRICOR tablets, 48/145 mg.

Renal method: eGFR in mL/min/1.73 m2.
Retrieved: 2026-09-07

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 2 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

formulation difference

Fenofibrate renal starting strengths are product-specific

TRICOR uses its own starting strength. ANTARA, LIPOFEN and FENOGLIDE have different strengths; TRIGLIDE has a distinct lower-dose availability restriction.

How to use this: Confirm the dispensed formulation and its own renal instructions. Do not apply a generic milligram-equivalence rule.

GlobalRPh RX List - TRICORFenofibrate (ANTARA)Fenofibrate (LIPOFEN)Fenofibrate tablets (FENOGLIDE)Fenofibrate tablets (TRIGLIDE)Fenofibric acid (FIBRICOR)

Source-specific interpretation; independent clinician adjudication pending.

source quality hold

Source-identity hold: title strength does not match capsule description

The separate RX fenofibrate-drug page is titled 40/120 mg but describes 50/150 mg capsules. No renal dosing from that mismatched page was imported in v4.1.

How to use this: Use the verified named-product source, not the held generic page. See the F audit entry for its retrieval reference. This is a source-quality problem, not a clinical disagreement.

GlobalRPh RX List - TRICOR

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeGlobalRPh RX List - TRICOR
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

TRICOR 48/145 mg formulation-specific source; do not substitute strengths from other fenofibrate formulations.

Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/fenofibrate/

Usual Dosing (Adults)

Primary hypercholesterolemia or mixed dyslipidemia: initial 145 mg daily. Severe hypertriglyceridemia: initial 48 to 145 mg daily. Maximum 145 mg. May take without regard to meals.

GRPH-fenofibrate-01 · Source section: Usual Dosing (Adults)Renal section finder

Renal Dosing

Mild to moderate renal impairment: initiate TRICOR at 48 mg/day; increase only after evaluating renal function and lipids at that dose. Avoid in severe impairment. For geriatric patients, choose dosage based on renal function.

GRPH-fenofibrate-02 · Source section: Renal DosingRenal section finder

Hemodialysis

Avoid TRICOR in severe renal impairment.

GRPH-fenofibrate-03 · Source section: HemodialysisRenal section finder
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - TRICOR

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Fenofibrate TRICOR tablets, 48/145 mg.

Renal method: eGFR in mL/min/1.73 m2.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

eGFR 30 to <60 mL/min/1.73 m2: start 48 mg orally once daily. Increase only after assessing renal function and triglyceride response. Use is contraindicated at eGFR <30 mL/min/1.73 m2, including ESRD and dialysis. Assess renal function before treatment and periodically during therapy. The starting strength belongs to this named product.

RDM41-rxlist-fenofibrate-39c9e6f0a8-C1 · Source locator: Dosage / Use in specific populations: renal impairment

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/tricor-drug/
Retrieved
2026-09-07
Renal-function method
eGFR in mL/min/1.73 m2.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
29ad71b0cccadc8fe76dfdc606c9a8acc02b53f94266d17c019a9bb9b45124ac

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/fenofibrate/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
493a22c925a1bd87fc55dc1a1708db259ddae5639705022ddcbc600eafb9c090
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report